secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001746473-23-000051
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics reports Q2 loss of $41.2M; initiates Phase 2b IPF trial, expects PSC data Q3 2023
--------------------------------------------------------------------------------

- Net loss $41.2M vs $29.5M prior year; R&D $33.0M, G&A $14.6M.
- Cash, equivalents & short-term investments $555.2M; sufficient into H2 2026.
- Initiated Phase 2b BEACON-IPF trial of bexotegrast in IPF (~270 patients, 160/320 mg).
- INTEGRIS-PSC Phase 2a 12-week interim data from 40/80/160 mg cohorts expected Q3 2023.
- Promoted Dr. Scott Turner to Chief Scientific Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647323000051/0001746473-23-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647323000051/plrx-20230809.htm
  HTML page:      https://secwatch.observer/filing/0001746473-23-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer